Prostate Cancer International is
for 2011 by Great NonProfits
The key prostate cancer presentations today at the annual meeting of the American Society of Clinical Oncology (ASCO) were all given at a morning session on high-risk and advanced prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, MDV3100 | 2 Comments »
According to a new report just issued by PhRMA, the pharmaceutical company trade group believes there are currently a total of 94 drugs in clinical development by its members specifically for the treatment of some form of prostate cancer.
Filed under: Drugs in development | Leave a Comment »
An article in The Washington Post today discusses an initiative through which a group of about 40 specialists in the management of advanced forms of genitourinary cancers (including prostate cancer) get together to share ideas and knowledge to help their patients.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, GUMDROP, referral, trials | Leave a Comment »
According to information on the web site of the National Institute for Clinical Excellence (NICE), revised draft guidance has been issued by NICE regarding the routine use of abiraterone acetate.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, access, NICE, UK | 1 Comment »
According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical [...]
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: abiraterone, dutasteride, enzalutamide, leuprolide, MDV3100, neoadjuvant, pre-surgical | 6 Comments »
According to an article in the online issue of Oncology Business Review (see page 12 of OBR Green), the full results of the clinical trial of abiraterone acetate + prednisone vs. placebo + prednisone in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer (mCRPC) will — as previously suggested — be presented at the upcoming annual [...]
Filed under: Drugs in development, Management, Treatment | 3 Comments »
For those who are interested in seeing a 30-minute video of a presentation and discussion about the development of new drugs like abiraterone, MDV3100, TAK-700 (orteronel), and others, just click here. This video comes from a continuing medical education activity presented in association with the Genitourinary Cancers symposium in San Francisco back in February.
Filed under: Drugs in development, Management | 2 Comments »
An article just published in Cancer Research this week suggests that adding the investigational agent enzalutamide (MDV3100) to abiraterone acetate and prednisone in men being treated for metastatic, castration-resistant prostate cancer (mCRPC) may be able to further delay disease progression among men showing signs of progression after initial treatment with abiraterone acetate.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, enzalutamide, mCRPC, MDV3100 | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site